Synthesis of heterocyclic enol ethers and their use as group 2 metabotropic glutamate receptor antagonists
摘要:
Heterocyclic enol ethers of type 1 were studied with respect to the inhibition of 1S,3R-ACPD (10 mu M)stimulated GTP gamma(35)S binding on rat mGluR2 transfected cell membranes. The structure activity relationship with regard to the substitution pattern of the phenyl ring, the oxygen substituent and the nature of the heterocycle is discussed, (C) 1999 Elsevier Science Ltd. All rights reserved.
The present invention provides compounds of the formula
which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, type 2 diabetes and obesity.
The present invention provides compounds of the formula
which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, type 2 diabetes and obesity.
Tricyclic compounds having fungicidal activity, their preparation and their use
申请人:SANKYO COMPANY LIMITED
公开号:EP0807631A1
公开(公告)日:1997-11-19
Compounds of formula (I):
[in which: R1 represents halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, or cycloalkyloxy; R2 represents hydrogen or halogen; R3 represents hydrogen, alkyl, or cycloalkyl; and the dotted line represents a single or double carbon-carbon bond]; and salts thereof have valuable fungicidal activities which make them of considerable value in agriculture and horticulture.
Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
申请人:Novartis AG
公开号:EP2298779A1
公开(公告)日:2011-03-23
The present invention provides compounds of the formula
which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (1) may be employed for the prevention and the-treatment of impaired glucose tolerance, type 2 diabetes and obesity,